吲哚菁绿15分钟滞留率对肝癌合并门静脉高压症患者经颈静脉肝内门体分流术后肝性脑病发生风险的预测价值

王重; 岳振东; 赵洪伟; 王磊; 范振华; 吴一凡; 董成宾; 张裕; 刘福全

doi:10.3969/j.issn.1001-5256.2020.09.017

吲哚菁绿15分钟滞留率对肝癌合并门静脉高压症患者经颈静脉肝内门体分流术后肝性脑病发生风险的预测价值

DOI: 10.3969/j.issn.1001-5256.2020.09.017

首都医科大学附属北京世纪坛医院介入治疗科

基金项目:

首都卫生发展科研专项(2018-1-2081)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1661
- HTML全文浏览量: 42
- PDF下载量: 118
- 被引次数: 5
出版历程
- 出版日期: 2020-09-20

Value of indocyanine green retention rate at 15 minutes in predicting the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in liver cancer patients with portal hypertension

Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University

Research funding:

摘要

摘要:
目的分析吲哚菁绿15 min滞留率（ICG-R15）、Child-Turcotte-Pugh（CTP）分级和终末期肝病模型（MELD）评分预测肝癌合并门静脉高压症患者经颈静脉肝内门体分流术（TIPS）后肝性脑病（HE）发生的临床价值。方法回顾性分析2015年1月-2017年6月在首都医科大学附属北京世纪坛医院经TIPS治疗的95例肝癌合并门静脉高压症患者的临床资料,根据TIPS术后是否发生HE分为HE组（n=24）和非HE组（n=71）;所有患者术前均进行ICG-R15测定、CTP分级、MELD评分。计量资料满足正态分布的2组间比较采用t检验,不满足正态分布的2组间比较采用Mann-Whitney U检验,计数资料2组间比较采用χ2检验和Fisher精确检验。采用单因素、多因素logistic回归分析TIPS术后HE发生相关的危险因素。采用受试者工作特征曲线（ROC曲线）分析比较ICG-R15、CTP和MELD评分对HE发生的预测价值。结果 TIPS术后12个月内HE发生率为25.2%（24/95）。logistic单因素分析显示,TIPS术后HE发生的相关因素有支架位置（P=0.02...
- 肝肿瘤 /
- 吲哚花菁绿 /
- 高血压,门静脉 /
- 门体分流术,经颈静脉肝内 /
- 肝性脑病
Abstract:
Objective To investigate the clinical value of indocyanine green retention rate at 15 minutes( ICG-R15),Child-Turcotte-Pugh( CTP) class,and Model for End-Stage Liver Disease( MELD) score in predicting post-transjugular intrahepatic portosystemic shunt( TIPS) hepatic encephalopathy( HE) in liver cancer patients with portal hypertension. Methods A retrospective analysis was performed for the clinical data of 95 liver cancer patients with portal hypertension who underwent TIPS in Department of Interventional Therapy in Beijing Shijitan Hospital from January 2015 to June 2017,and according to the presence or absence of HE after TIPS,they were divided into HE group with 24 patients and non-HE group with 71 patients. ICG-R15,CTP class,and MELD score were determined for all patients before surgery. The t-test was used for comparison of normally distributed continuous data between two groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test and the Fisher's exact test were used for comparison of categorical data between two groups. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for HE after TIPS,and the receiver operating characteristic( ROC) curve was used to analyze the value of ICG-R15,CTP class,and MELD score in predicting HE. Results The incidence rate of HE was 25. 2%( 24/95) within 12 months after TIPS. The univariate analysis showed that stent location( P = 0. 021),ICG-R15( P = 0. 005),and CTP class( P = 0. 040) were associated with HE after TIPS. The multivariate analysis showed that stent located in the right portal vein( OR = 3. 373,95% CI: 2. 346 ～ 5. 103,P = 0. 010) and ICG-R15 > 30%( OR = 2. 107,95% CI: 1. 331 ～ 3. 212,P = 0. 036) were independent risk factors for HE after TIPS in liver cancer patients with portal hypertension. The ROC curve analysis showed that ICG-R15,MELD score,and CTP class had an area under the ROC curve of 0. 659,0. 638,and 0. 621,respectively,in predicting HE after TIPS. Conclusion ICG-R15 has a certain clinical value in predicting HE after TIPS in liver cancer patients with portal hypertension.
- liver neoplasms /
- indocyanine green /
- hypertension,portal /
- portasystemic shunt,transjugular intrahepatic /
- hepatic encephalopathy

HTML全文

参考文献(19)

[1] Cancer minimally invasive therapy professional committee of china cancer association,Asian society for tumor ablation.Minimally invasive and multi-disciplinary comprehensive diagnosis and treatment of hepatocellular carcinoma:2018guangzhou consensus[J]. J Clin Hepatol,2019,35(10):2176-2184.(in Chinese)亚太影像引导下肿瘤微创治疗协会，中国抗癌协会肿瘤微创治疗专业委员会，亚洲肿瘤消融学会．肝细胞癌微创与多学科综合诊疗———2018广州共识[J]．临床肝胆病杂志，2019,35(10):2176-2184.

[2] SANKAR K,MOORE CM. Transjugular intrahepatic portosystemic shunts[J]. JAMA,2017,317(8):880.

[3] ROWLEY MW,CHOI M,CHEN S,et al. Refractory hepatic encephalopathy after elective transjugular intrahepatic portosystemic shunt:Risk factors and outcomes with revision[J].Cardiovasc Intervent Radiol,2018,41(11):1765-1772.

[4] KRAGLUND F,JEPSEN P,AMANAVICIUS N,et al. Longterm effects and complications of the transjugular intrahepatic portosystemic shunt:A single-centre experience[J]. Scand J Gastroenterol,2019,54(7):899-904.

[5] KOKUDO T,HASEGAWA K,AMIKURA K,et al. Assessment of preoperative liver function in patients with hepatocellular carcinoma-The Albumin-Indocyanine Green Evaluation(ALICE)grade[J]. PLo S One,2016,11(7):e0159530.

[6] WANG YY,ZHAO XH,MA L,et al. Comparison of the ability of Child-Pugh score,MELD score,and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma[J]. J Surg Oncol,2018,118(3):440-445.

[7] AZUMI M,SUDA T,TERAI S,et al. Prognostic impact of indocyanine green plasma disappearance rate in hepatocellular carcinoma patients after radiofrequency ablation:A prognostic nomogram study[J]. Intern Med,2017,56(9):1001-1007.

[8] SONG P,INAGAKI Y,WANG Z,et al. High levels of gammaglutamyl transferase and indocyanine green retention rate at 15min as preoperative predictors of tumor recurrence in patients with hepatocellular carcinoma[J]. Medicine(Baltimore),2015,94(21):e810.

[9] LLOVET JM,ZUCMAN-ROSSI J,PIKARSKY E,et al. Hepatocellular carcinoma[J]Nat Rev Dis Primers,2016,2:16018.

[10] International group,Chinese Society of Radiology,Chinese medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol,2017,33(7):1218-1228.(in Chinese)中华医学会放射学分会介入学组．经颈静脉肝内门体分流术专家共识[J]．临床肝胆病杂志，2017,33(7):1218-1228.

[11] ZOU H,YANG X,LI Q L,et al. A comparative study of albumin-bilirubin score with child-pugh score,model for endstage liver disease score and indocyanine green r15 in predicting posthepatectomy liver failure for hepatocellular carcinoma patients[J]. Dig Dis,2018,36(3):236-243.

[12] SIA D,VILLANUEVALL A,FRIEDMAN SL,et al. Liver cancer cell of origin,molecular class,and effects on patient prognosis[J]. Gastroenterology,2017,152(4):745-761.

[13] FERLAY J,SOERJOMATARM I,DIKSHIT R,et al. Cancer incidence and mortality worldwide:Sources,methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):e359-e386.

[14] MARENOGO A,ROSSO C,BUGIANESI E. Liver cancer:Connections with obesity,fatty liver,and cirrhosis[J]. Annu Rev Med,2016,67:103-117.

[15] MONTAGNESE S,RUSSO FP,AMODIO P,et al. Hepatic encephalopathy 2018:A clinical practice guideline by the Italian Association for the Study of the Liver(AISF)[J]. Dig Liver Dis,2019,51(2):190-205.

[16] HIWATASHIL K,UENO S,SAKODA M,et al. The evaluation of liver function and surgical influence by ICGR15 after chemotherapy for colorectal liver metastases[J]. J Cancer,2016,7(5):595-599.

[17] HE F,DAI S,XIAO Z,et al. Pathological predictors of shunt stenosis and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Biomed Res Int,2016,2016:3681731.

[18] LUO SH,CHU JG,HUANG H,et al. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy[J].World J Gastroenterol,2019,25(9):1088-1099.

[19] KAPLAN DE,DAI F,AYTAMAN A,et al. Development and performance of an algorithm to estimate the child-turcottepugh score from a national electronic healthcare database[J]. Clin Gastroenterol Hepatol,2015,13(13):2333-2341. e1-6.

施引文献

期刊类型引用(3)

1.	周晓菊，邓威，杨丽. 医学检验科检查肝硬化疾病的临床应用价值. 黑龙江医学. 2024(11): 1340-1342 . 百度学术
2.	张琳，冯晓彬，黄鑫，梁子威，何作祥，卢倩，董家鸿. 钇-90微球选择性内放射治疗在肝癌降期转化移植中的应用进展. 中华消化外科杂志. 2024(12): 1566-1570 . 百度学术
3.	余敏，李歆. 528例卡瑞利珠单抗治疗的免疫相关不良反应及风险因素分析. 中国药物警戒. 2023(10): 1134-1140 . 百度学术